Kirin Pharma Company, Limited
GPTKB entity
Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Kyowa Hakko Kirin
|
| gptkbp:employees |
Approximately 5,000
|
| gptkbp:focusArea |
Immunology
Oncology Neurology Infectious diseases |
| gptkbp:founded |
1907
|
| gptkbp:headquarters |
gptkb:Tokyo,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kirin Pharma Company, Limited
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:keyPeople |
gptkb:Yoshinori_Isozaki
|
| gptkbp:market |
gptkb:Asia
gptkb:Japan Global |
| gptkbp:parentCompany |
gptkb:Kirin_Holdings_Company,_Limited
|
| gptkbp:partnerships |
Various global pharmaceutical companies
|
| gptkbp:products |
Prescription drugs
Over-the-counter drugs |
| gptkbp:researchAndDevelopment |
Innovative drug development
|
| gptkbp:revenue |
$3.5 billion (2020)
|
| gptkbp:subsidiary |
Kirin Pharma USA, Inc.
|
| gptkbp:website |
www.kirin.co.jp/en/
|